fluorouracil has been researched along with Kidney Failure in 16 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age ≥ 65 with early-stage breast cancer." | 3.83 | Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. ( Cirrincione, CT; Cohen, HJ; Gralow, J; Hurria, A; Jatoi, A; Lichtman, SM; Magrinat, G; Morganstern, DE; Muss, HB; Theodoulou, M; Wolff, AC, 2016) |
| "The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies." | 3.01 | Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023) |
| " We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT." | 2.73 | Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. ( Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| "She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
| "Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment." | 1.51 | Evaluating dose of cisplatin responsible for causing nephrotoxicity. ( Higuchi, K; Yanagawa, T, 2019) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function." | 1.43 | Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. ( Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016) |
| "Toxicity was acceptable, with grade 3 renal failure (n=1) and grade 3 or 4 myelotoxicity (n=2)." | 1.43 | Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. ( Dietrich, PY; Espeli, V; Hottinger, AF; Modarressi, A; Ruegg, E, 2016) |
| "Capecitabine (Xeloda) is an orally administered precursor of 5'deoxy-5-fluorouridine, which is a preferentially activated to 5-fluorouracil in tumors." | 1.38 | A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. ( Flombaum, C; Jhaveri, KD; Latcha, S; Shah, M, 2012) |
| "We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m(2) on day 1 and continuous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total)." | 1.34 | Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. ( Ciammella, P; Clerico, M; Filippi, AR; Franco, P; Giudici, M; Munoz, F; Ricardi, U, 2007) |
| "Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU)." | 1.32 | A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). ( Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Carriat, L | 1 |
| Quaranta, S | 1 |
| Solas, C | 1 |
| Rony, M | 1 |
| Ciccolini, J | 1 |
| Mayanagi, S | 1 |
| Oba, K | 1 |
| Aoyama, T | 1 |
| Tanaka, K | 1 |
| Kanda, M | 1 |
| Honda, M | 1 |
| Maeda, H | 1 |
| Kashiwabara, K | 1 |
| Muto, M | 1 |
| Sakamoto, J | 1 |
| Yamagishi, H | 1 |
| Yoshikawa, T | 1 |
| Takeuchi, M | 1 |
| Imamura, CK | 2 |
| Booka, E | 2 |
| Takeuchi, H | 2 |
| Mizukami, T | 2 |
| Kawakami, T | 1 |
| Funakoshi, T | 1 |
| Wakuda, K | 1 |
| Aoki, Y | 1 |
| Hamamoto, Y | 2 |
| Kitago, M | 1 |
| Kawakubo, H | 2 |
| Boku, N | 2 |
| Tanigawara, Y | 2 |
| Kitagawa, Y | 2 |
| Gelen, V | 1 |
| Şengül, E | 1 |
| Yıldırım, S | 1 |
| Senturk, E | 1 |
| Tekin, S | 1 |
| Kükürt, A | 1 |
| Miyagawa, F | 1 |
| Sugano, Y | 1 |
| Sho, M | 1 |
| Asada, H | 1 |
| Higuchi, K | 1 |
| Yanagawa, T | 1 |
| Huelster, HL | 1 |
| Hogan, MMS | 1 |
| Resnick, MJ | 1 |
| Hayakawa, Y | 1 |
| Kobayashi, K | 1 |
| Sakamoto, N | 1 |
| Matsuoka, M | 1 |
| Nozaka, T | 1 |
| Misumi, Y | 1 |
| Matsumoto, T | 1 |
| Miura, N | 1 |
| Furumoto, Y | 1 |
| Asano, T | 1 |
| Horiuchi, T | 1 |
| Fujiki, K | 1 |
| Ho, MY | 1 |
| Kennecke, HF | 1 |
| Renouf, DJ | 1 |
| Cheung, WY | 1 |
| Lim, HJ | 1 |
| Gill, S | 1 |
| Gomi, D | 1 |
| Ichiyama, T | 1 |
| Tateishi, K | 1 |
| Takahashi, T | 1 |
| Soejima, K | 1 |
| Lichtman, SM | 1 |
| Cirrincione, CT | 1 |
| Hurria, A | 1 |
| Jatoi, A | 1 |
| Theodoulou, M | 1 |
| Wolff, AC | 1 |
| Gralow, J | 1 |
| Morganstern, DE | 1 |
| Magrinat, G | 1 |
| Cohen, HJ | 1 |
| Muss, HB | 1 |
| Espeli, V | 1 |
| Ruegg, E | 1 |
| Hottinger, AF | 1 |
| Modarressi, A | 1 |
| Dietrich, PY | 1 |
| Jhaveri, KD | 1 |
| Flombaum, C | 1 |
| Shah, M | 1 |
| Latcha, S | 1 |
| O'Donnell, A | 1 |
| Punt, CJ | 1 |
| Judson, I | 1 |
| Van Maanen, L | 1 |
| Suttle, AB | 1 |
| Ertel, P | 1 |
| Beale, P | 1 |
| Munoz, F | 1 |
| Franco, P | 1 |
| Ciammella, P | 1 |
| Clerico, M | 1 |
| Giudici, M | 1 |
| Filippi, AR | 1 |
| Ricardi, U | 1 |
| Inoue, S | 1 |
| Ohtani, H | 1 |
| Tsujimoto, M | 1 |
| Hori, S | 1 |
| Sawada, Y | 1 |
1 review available for fluorouracil and Kidney Failure
| Article | Year |
|---|---|
Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; East A | 2023 |
2 trials available for fluorouracil and Kidney Failure
| Article | Year |
|---|---|
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2007 |
13 other studies available for fluorouracil and Kidney Failure
| Article | Year |
|---|---|
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
The protective effects of hesperidin and curcumin on 5-fluorouracil-induced nephrotoxicity in mice.
Topics: Animals; Antioxidants; Curcumin; Fluorouracil; Glutathione; Hesperidin; Humans; Kidney; Malondialdeh | 2021 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluo | 2017 |
Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationsh | 2019 |
Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Disease Progress | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capeci | 2016 |
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marr | 2016 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; D | 2012 |
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Therapy, Combination; Enzym | 2003 |
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease | 2007 |